Payment overview · 2025
General Payments
$1,104.58
27 reported records · 12 companies
Healthcare provider profile · identity verified
David Robert Axline, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · NAPLES, FL · NPI 1023002003
Verified facts
What the public records show
CMS Open Payments records show David Robert Axline, M.D. received $1,104.58 in general payments during 2025 across 27 reported records.
Medtronic, Inc. accounted for 30.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$334.30 | 30.3% | 5 | 2025 |
| ZOLL Circulation Inc | Unresolved — no canonical attribution shown | $168.50 | 15.2% | 1 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $168.30 | 15.2% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $156.23 | 14.1% | 9 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $88.88 | 8.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.41 | 4.0% | 3 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $34.24 | 3.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $29.00 | 2.6% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $28.81 | 2.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.30 | 2.1% | 1 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $17.72 | 1.6% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $10.89 | 1.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,104.58 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AZURE XT DR MRI SURESCAN Normalized: azure xt dr mri surescan |
Device | Medtronic, Inc. | $206.85 | 2 | 2025 |
Source payment records
|
|||||
| Catheter Normalized: catheter |
Device | ZOLL Circulation Inc | $168.50 | 1 | 2025 |
Source payment records
|
|||||
| Temperature Management System Normalized: temperature management system |
Device | ZOLL Circulation Inc | $168.50 | 1 | 2025 |
Source payment records
|
|||||
| Temperature Management System Start-Up Kit Normalized: temperature management system start up kit |
Device | ZOLL Circulation Inc | $168.50 | 1 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $168.30 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $156.23 | 9 | 2025 |
Source payment records
|
|||||
| PASCAL Normalized: pascal |
Device | Edwards Lifesciences Corporation | $88.88 | 1 | 2025 |
Source payment records
|
|||||
| AURORA EV-ICD MRI SURESCAN Normalized: aurora ev icd mri surescan |
Device | Medtronic, Inc. | $84.58 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.41 | 3 | 2025 |
Source payment records
|
|||||
| COBALT DR MRI SURESCAN Normalized: cobalt dr mri surescan |
Device | Medtronic, Inc. | $42.87 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $34.24 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $34.24 | 1 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $29.00 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $28.81 | 1 | 2025 |
Source payment records
|
|||||
| KENGREAL Normalized: kengreal |
Drug | Chiesi USA, Inc. | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $10.89 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 980 | 316 |
| Eliquis | Apixaban | 855 | 232 |
| Atorvastatin Calcium | Atorvastatin Calcium | 723 | 222 |
| Amlodipine Besylate | Amlodipine Besylate | 495 | 163 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 391 | 127 |
| Lisinopril | Lisinopril | 347 | 105 |
| Losartan Potassium | Losartan Potassium | 340 | 116 |
| Carvedilol | Carvedilol | 319 | 102 |
| Furosemide | Furosemide | 291 | 104 |
| Xarelto | Rivaroxaban | 242 | 71 |
| Warfarin Sodium | Warfarin Sodium | 237 | 77 |
| Metoprolol Tartrate | Metoprolol Tartrate | 226 | 76 |
| Clopidogrel | Clopidogrel Bisulfate | 209 | 66 |
| Ezetimibe | Ezetimibe | 208 | 70 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 175 | 51 |
| Valsartan | Valsartan | 158 | 50 |
| Spironolactone | Spironolactone | 145 | 45 |
| Entresto | Sacubitril/Valsartan | 135 | 41 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 131 | 42 |
| Jardiance | Empagliflozin | 118 | 28 |
| Simvastatin | Simvastatin | 111 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 106 | 37 |
| Digoxin | Digoxin | 93 | 27 |
| Atenolol | Atenolol | 91 | 32 |
| Nitroglycerin | Nitroglycerin | 77 | 53 |
| Flecainide Acetate | Flecainide Acetate | 74 | 22 |
| Amiodarone Hcl | Amiodarone Hcl | 71 | 23 |
| Repatha Sureclick | Evolocumab | 71 | 21 |
| Potassium Chloride | Potassium Chloride | 70 | 27 |
| Ranolazine Er | Ranolazine | 66 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 21 |
| Jantoven | Warfarin Sodium | 58 | 22 |
| Torsemide | Torsemide | 56 | 17 |
| Praluent Pen | Alirocumab | 50 | suppressed |
| Chlorthalidone | Chlorthalidone | 48 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 39 | 13 |
| Ramipril | Ramipril | 35 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 28 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,104.58 · 27 records | Medtronic, Inc. | AURORA EV-ICD MRI SURESCAN, AZURE XT DR MRI SURESCAN, Barostim Neo System, COBALT DR MRI SURESCAN, Catheter, Cleerly Ischemia, Cleerly Labs, FARAPULSE, FUROSCIX, KENGREAL, LifeVest, PASCAL, REPATHA, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Temperature Management System, Temperature Management System Start-Up Kit | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error